Codex

Cigna is two businesses with very different economics: Evernorth moves enormous pharmacy volume at thin margins, while Cigna Healthcare turns a much smaller revenue base into a larger share of profit by pricing medical risk and admin fees correctly. The market often frames CI as just another managed-care stock, but the real question is whether Evernorth's scale economics and Cigna Healthcare's underwriting discipline can both hold during the rebate-model transition and after the Medicare Advantage exit on March 19, 2025.

How This Business Actually Works

Takeaway: Evernorth produces the volume, but Cigna Healthcare still produces more profit per dollar of revenue.

Evernorth is basically a toll road on drug spend. It wins huge employer, health plan and government contracts, adjudicates claims, manages formularies and rebates, and then routes more valuable specialty and home-delivery volume through owned assets. That is why volume matters so much: the better the claim volume and specialty mix, the more leverage Cigna has with pharmacies, manufacturers and wholesalers.

Cigna Healthcare is a different animal. About 79% of medical customers are ASO, where Cigna mostly earns fees and network access with limited claims risk, but 68% of segment revenue still comes from insured products, where pricing errors show up fast in the medical care ratio. Incremental profit comes from keeping Evernorth's affordability economics, growing specialty volume, and repricing insured and stop-loss business faster than utilization rises. Management also says Evernorth's three largest clients are renewed through the end of the decade, which helps visibility but also tells you concentration is real.

The Playing Field

Takeaway: CI sits in the industry's middle ground: more diversified than a pure insurer, but without UnitedHealth's clear margin leadership.

The best peer is still UnitedHealth, because Optum shows what this model looks like when the services platform has both scale and superior economics. Elevance is the cleaner insurance comparison. CVS proves that more vertical integration does not automatically mean better returns. Humana, Centene and Molina show the other side of the business: when government-heavy books are mispriced, membership can look fine while margins fall apart.

Cigna's real advantage is not a magical moat. It is a useful but fragile combination of PBM scale, specialty assets, and a large ASO employer base that gives it data, network relevance and cross-sell opportunities. What good looks like in this industry is simple: keep service volumes growing, avoid giving all of that value back in pricing, and do not let insured medical trend outrun premiums.

Is This Business Cyclical?

Takeaway: The cycle hits CI through medical utilization and pricing lag, not through classic demand destruction.

The cleanest example is COVID. Deferred care pushed Cigna Healthcare's medical care ratio down to 78.3% in 2020, then the snapback in testing, treatment, vaccines and deferred procedures drove it up to 84.0% in 2021. The next leg was normal rate and utilization management: 81.7% in 2022 and 81.3% in 2023. Then the pressure returned through stop-loss in 2024 and individual-market medical costs in 2025, even after the Medicare Advantage sale.

That is why this business should be read as a pricing and claims-management cycle, not an economic volume cycle. Evernorth can keep growing scripts while the insured book gets squeezed, and consolidated free cash flow can stay sturdy even when one underwriting pocket has a bad year. The analyst mistake is to watch membership first and MCR second. The order should be reversed.

The Metrics That Actually Matter

Takeaway: Four numbers explain most of the value creation: scripts, Evernorth margin, medical care ratio, and free-cash-flow margin.

Scripts come first because scale is what gets Evernorth a seat at the table with large employers, pharmacies and manufacturers. Evernorth margin comes second because volume without retained economics is not worth much. Medical care ratio is the key risk gauge because a 100 bps miss in the insured book can erase a lot of PBM progress. Free-cash-flow margin is the quality check: it tells you whether accounting growth is still turning into cash after capex and working capital. Adjusted EPS is useful, but only as the output of these drivers, not the starting point.

What I'd Tell a Young Analyst

Takeaway: Start with unit economics, not the headline multiple.

Watch Evernorth like a distributor with bargaining power, not like a software company with naturally expanding margins. If claim volume grows but Evernorth pre-tax margin keeps bleeding lower, scale is helping clients more than shareholders. Watch Cigna Healthcare like an underwriter: stop-loss severity, individual-market pricing, and medical care ratio matter more than raw membership.

The thesis gets better if the rebate-free PBM transition protects retention and holds Evernorth near its current margin band while Cigna Healthcare brings MCR back under control. The thesis gets worse if CI needs repeated catch-up pricing in stop-loss and IFP while Evernorth gives up economics to defend volume. That is the whole game.